Clinical trial
Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01786174 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2013
- Completion date
- May 31, 2015
- Enrollment
- 30 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.